Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775).

导出 LinkOut

翻译打印收藏纠错

作者： Simon D,Brandt ^[1] ; Pierce V,Kavanagh ^[2] ; Brendan,Twamley ^[3] ; Folker,Westphal ^[4] ; Simon P,Elliott ^[5] ; Jason,Wallach ^[6] ; Alexander,Stratford ^[7] ; Landon M,Klein ^[8] ; John D,McCorvy ^[9] ; David E,Nichols ^[10] ; Adam L,Halberstadt ^[11]

作者单位： School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK. ^[1] Department of Pharmacology and Therapeutics, School of Medicine, Trinity Centre for Health Sciences, Dublin 8, Ireland. ^[2] School of Chemistry, Trinity College Dublin, Dublin 2, Ireland. ^[3] Section Narcotics/Toxicology, State Bureau of Criminal Investigation Schleswig-Holstein, Kiel, Germany. ^[4] Alere Forensics, Malvern Hills Science Park, Malvern, UK. ^[5] Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, Pennsylvania, USA. ^[6] Synex Synthetics BV, Delft, The Netherlands. ^[7] Department of Neurosciences, University of California San Diego, La Jolla, California, USA. ^[8] Department of Pharmacology, University of North Carolina, Chapel Hill, North Carolina, USA. ^[9] Division of Chemical Biology and Medicinal Chemistry, University of North Carolina, Chapel Hill, North Carolina, USA. ^[10] Department of Psychiatry, University of California San Diego, La Jolla, California, USA. ^[11]

关键词 5-HT2A receptor LSD lysergamides new psychoactive substances psychedelics